Voyager Therapeutics, Inc.
Key Metrics
- Previous Close
- $1.52
- 52-Week Range
- $1.48 – $5.48
- Market Cap
- $103.92M
- P/E (TTM)
- —
- EPS (TTM)
- -1.74
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.77
- PEG Ratio
- —
- Return on Equity
- -58.90%
- Return on Assets
- -29.42%
- Gross Margin
- 0.00%
- Operating Margin
- -436.18%
- Profit Margin
- 0.00%
- Current Ratio
- 6.81
- Debt/Equity
- 0.23
- Total Debt
- $30.51M
- Free Cash Flow
- $-68.50M
- Revenue Growth
- -70.00%
- Earnings Growth
- —
- Enterprise Value
- $27.62M
Market Snapshot
About
Voyager Therapeutics is a clinical-stage gene therapy company developing treatments for severe neurological diseases. The company focuses on leveraging advanced adeno-associated virus (AAV) capsids and payloads to deliver transformative therapies for conditions including Parkinson disease, Alzheimer disease, and other central nervous system disorders.